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Resumo 
  
Nas últimas décadas, tem ocorrido um aumento na prevalência de doenças 
metabólicas e cardiovasculares, o que representa um problema de saúde alarmante. Assim, 
é necessário esclarecer os mecanismos fisiopatológicos subjacentes a estas, de forma a 
desenvolver novas intervenções terapêuticas.  
Os corpos carotídeos (CBs) são quimiorrecetores periféricos que têm como principal 
estímulo, a hipóxia, tendo sido propostos como sensores de glucose, implicados no controlo 
da homeostasia energética. Recentemente, foi descrito que a disfunção destes está envolvida 
na génese da resistência à insulina e da hipertensão arterial.  
Assim, o principal objetivo deste trabalho foi estudar a abolição da atividade do CB 
como uma possível intervenção terapêutica para a reversão da resistência à insulina e da 
hipertensão. Para isso, foram utilizados dois modelos animais, submetidos a dietas 
hipercalóricas, o modelo de dieta rica em sacarose (HSu), que é um modelo magro de 
resistência à insulina e hipertensão, e o modelo de dieta rica em lípidos (HF), que é um modelo 
combinado de obesidade, resistência à insulina e hipertensão, e que foi mantido numa dieta 
rica em lípidos.  
A abolição da atividade do corpo carotídeo foi realizada através da ressecção do nervo 
do seio carotídeo (CSN). Parâmetros como sensibilidade à insulina, glicemia em jejum, níveis 
plasmáticos de insulina, variação de peso e gordura, perfil lipídico, níveis de ácidos gordos 
livres e expressão do recetor de insulina e dos transportadores de glucose Glut4 e Glut2, 
foram avaliadas.  
Observou-se que as dietas hipercalóricas alteraram os parâmetros acima 
mencionados. No entanto, a ressecção do CSN restaurou completamente a sensibilidade à 
insulina, a glicemia em jejum e os níveis de insulina plasmática. Para além disso, também 
impediu o ganho de peso nos animais submetidos às dietas hipercalóricas, levando a uma 
diminuição da gordura total e visceral e a um melhor perfil lipídico. Além disso, a desnervação 
do CB levou, também, a um restauro dos níveis de recetor de insulina e de Glut4 no músculo-
esquelético, e dos níveis de Glut2 no fígado.  
Em conclusão, este estudo demonstrou que a abolição da atividade do CB pode ser 
utilizada como uma potencial intervenção terapêutica, destacando a importância do 
desenvolvimento de estratégias para reduzir a sobreactivação deste em doenças metabólicas.  
 
Palavras-chave: corpo carotídeo, ressecção do nervo do seio carotídeo, diabetes mellitus 
tipo 2, resistência à insulina, dislipidémia
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Abstract  
 
In the last decades there has been a dramatic increase in the prevalence of metabolic 
and cardiovascular diseases. This increase represents an alarming health problem urging 
quick clarification of the pathophysiological mechanisms that underlie these diseases in an 
attempt to develop therapeutic interventions. Carotid bodies (CB) are peripheral 
chemoreceptors whose main stimulus is hypoxia, and it was proposed that they can act as 
glucose sensors implicated in energy homeostasis control. Recently we have described that 
CB dysfunction is involved in the genesis of insulin resistance (IR) and hypertension (HT).  
Thus, the main goal of this project was to investigate if the abolishment of CB activity 
can be a potential therapeutic intervention to reverse IR and HT. For that, we have used 2 
pathological animal models, the high fat (HF) and the high sucrose (HSu) model. Abolishment 
of CB activity was performed through the resection of CB sensitive nerve, the carotid sinus 
nerve (CSN.) Insulin sensitivity, fasting plasma glucose and insulin levels, weight and fat 
variation, lipid profile, plasma free fatty acids (FFA) levels, insulin receptor expression and 
glucose transporters Glut4 and Glut2 expression, were evaluated in controls and in 
pathological animal models.  
We have observed that hypercaloric diets altered the parameters above mentioned. 
However, CSN resection completely restored insulin sensitivity, fasting plasma glucose and 
plasma insulin levels. Additionally, it also prevented additional weight gain in rats submitted to 
hypercaloric diets, leading to a decrease in total and visceral fat and to a better lipid profile. 
Furthermore, CSN denervation also restored IR and Glut4 levels in skeletal muscle and Glut2 
levels in liver. 
In conclusion, this study demonstrated that the abolishment of CB activity can be used as 
a potential therapeutic intervention, highlighting the importance of developing strategies to 
reduce CB overactivity in metabolic diseases. 
 
Key words: carotid body, carotid sinus nerve resection, type 2 diabetes, insulin resistance, 
dyslipidemia 
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Resumo 
 
A prevalência de doenças metabólicas como obesidade, resistência à insulina, 
hiperglicémia, hiperlipidémia e hipertensão tem vindo a aumentar drasticamente. Nas últimas 
duas décadas verificou-se um aumento no número de pessoas diagnosticadas com diabetes. 
Aliás, é estimado que em 2030 o número de pessoas com diabetes aumente para 439 milhões. 
Em Portugal, estima-se que 34% da população, entre os 20 e os 79 anos, sofram de diabetes 
ou pré-diabetes. Assim, tendo em conta esta epidemia, é de grande interesse identificar e 
implementar intervenções de forma a impedir ou retardar o seu aparecimento. 
A diabetes mellitus tipo 2 é uma patologia poligénica complexa, caracterizada pela 
presença de defeitos quer ao nível da secreção da insulina (disfunção as células β do 
pâncreas) quer ao nível da ação da insulina (resistência à insulina). Assim, a primeira 
anormalidade detetável na diabetes mellitus tipo 2 é uma redução da habilidade do organismo 
em responder à insulina, ou seja resistência à insulina. Nesta altura, o pâncreas consegue 
aumentar a secreção de insulina de forma a normalizar os níveis de glucose no plasma (pré-
diabetes) sendo esta fase caracterizada por resistência à insulina, normoglicémia e 
hiperinsulinémia. Contudo, com o tempo, as células β não conseguem manter a alta secreção 
de insulina, o que resulta no desenvolvimento de intolerância à glucose e eventualmente, 
diabetes. 
Os corpos carotídeos são pequenos órgãos, localizados bilateralmente na bifurcação 
da artéria carótida. Estes órgãos são constituídos por dois tipos de células, as células tipo I 
(também chamadas de células quimiorrecetores) e as células tipo II (também chamadas de 
células de sustentação). Os corpos carotídeos são quimiossensores arteriais que detetam 
alterações nas pressões de O2, CO2 e Ph. Quando estes órgãos detetam hipóxia, hipercápnia 
ou acidose, as células quimorreceptoras libertam neurotransmissores que atuam nos seus 
recetores no nervo do seio carotídeo aumentando a frequência dos seus potenciais de ação. 
Esta atividade elétrica do nervo do seio carotídeo é integrada no tronco cerebral de forma a 
induzir um conjunto de reflexos respiratórios que irão normalizar, por hiperventilação, os gases 
sanguíneos alterados e que irão também regular a pressão sanguínea e a performance 
cardíaca, através da ativação do sistema nervoso simpático.  
Para além do seu papel no controlo cardiorespiratório, foi mais recentemente proposto 
que o corpo carotídio possa ser um sensor de glucose e que possa estar implicado no controlo 
da homeostasia da glucose e no controlo energético. Mais recentemente, foi também 
demonstrado o papel do corpo carotídeo na regulação da sensibilidade à insulina. Observou-
se que a atividade dos quimiorrecetores periféricos do corpo carotídeo está aumentada em 
modelos animais hipercalóricos de resistência à insulina e hipertensão e que a desnervação 
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crónica do nervo do seio carotídeo previne o desenvolvimento de resistência à insulina e 
hipertensão, o que significa que este órgão está envolvido na etiologia destas características 
patológicas presentes nas doenças metabólicas. Observou-se também que nestes modelos 
animais está presente uma sobreativação do sistema nervoso simpático e que a desnervação 
previne também este aumento, o que sugere que sobreativação do corpo carotídeo leva a um 
aumento da atividade do sistema nervoso simpático, iniciando assim um ciclo que levará a 
uma diminuição da sensibilidade à insulina e ao surgimento de hipertensão.  
Assim, o objetivo principal deste trabalho foi estudar a abolição da atividade do corpo 
carotídeo como uma possível intervenção terapêutica para a reversão da resistência à insulina 
e da hipertensão. Os objetivos específicos foram investigar em modelos animais de pré-
diabetes e síndrome metabólica: 1) se a resseção do nervo do seio carotídeo restaura a 
sensibilidade à insulina e a hiperinsulinémia; 2) o efeito da resseção do nervo do seio 
carotídeo no aumento de peso, na distribuição de gordura e no perfil lipídico e por último; 3) 
estudar os mecanismos moleculares pelos quais a resseção do nervo induz um efeito benéfico 
nos parâmetros metabólicos e cardiovasculares.  
 As experiências foram realizadas em ratos Wistar, de ambos os sexos e com 3 meses 
de idade que foram submetidos a dietas hipercalóricas de forma a induzir diabetes mellitus 
tipo 2 e síndrome metabólica. O modelo de dieta rica em sacarose (HSu), que é um modelo 
magro de resistência à insulina e hipertensão foi conseguido através da administração de 35% 
de sacarose na água de beber (durante 28 dias) enquanto que o modelo de dieta rica em 
lípidos (HF), que é um modelo combinado de obesidade, resistência à insulina e hipertensão, 
foi mantido numa dieta rica em lípidos (45% de gordura, 35% de carbohidratos e 20% de 
proteína) durante 21 dias). Paralelamente a estes grupos, um grupo de animais controlo foi 
mantido numa dieta standard. 
Após as dietas (3 semanas para os animais HF e 4 semanas para os HSu), a 
resistência à insulina foi confirmada através de um teste de tolerância à insulina (ITT) e os 
grupos de animais foram divididos. Metade do grupo de animais foi submetido à resseção 
bilateral do nervo do seio carotídeo e outra metade foi submetida ao mesmo procedimento 
cirúrgico, mas sem corte do nervo (grupo sham). Após estes procedimentos cirúrgicos, os 
animais foram mantidos nas suas dietas durante mais três semanas e vários parâmetros foram 
avaliados semanalmente (glicemia em jejum, sensibilidade à insulina e peso corporal). Para 
além disso, foi também monitorizada a ingestão calórica e de líquidos, diariamente, antes e 
após a cirurgia. 
No final deste período, os animais foram anestesiados com pentobarbital (60mg/kg 
i.p.), e foi confirmada a resseção do nervo do seio carotídeo através da ausência de respostas 
ventilatórias à hipoxia isquémica. De seguida foi recolhido sangue, por punção cardíaca, para 
quantificação da insulina plasmática e avaliação do perfil lipídico. Para além disso, também 
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foram colhidos tecidos como músculo-esquelético e fígado (para posterior homogeneização e 
análise de expressão de proteínas por Western Blot) e ainda gorduras totais e viscerais, que 
foram pesadas e posteriormente conservadas a -80ºC. 
A sensibilidade à insulina foi avaliada pelo teste de tolerância à insulina, o perfil lipídico 
foi avaliado pelo kit Randox, que avalia o colesterol total e os triglicéridos através ensaios 
enzimáticos colorimétricos, e o colesterol HDL e LDL através de métodos diretos de clearance. 
Por sua vez, os ácidos gordos livres foram avaliados através de teste colorimétrico. Para além 
disso foram também analisadas, por Western Blot, as expressões do recetor de insulina e do 
transportador de glucose Glut4 no músculo-esquelético e do transportador de glucose Glut2 
no fígado. 
 Tal como anteriormente descrito pelo nosso grupo, apenas a dieta HSu induziu um 
aumento na glicémia basal. Observou-se também que após 3 semanas de HF e 4 semanas 
de HSu, a sensibilidade à insulina se encontrava significativamente diminuída. Quanto aos 
níveis de insulina plasmática, ambas as dietas hipercalóricas produziram um aumento dos 
mesmos (hiperinsulinémia).  
 Após as dietas, ambos os modelos animais de HSu e HF apresentaram um elevado 
aumento de peso por dia, em comparação com os controlos. Contudo, apenas os animais 
submetidos à dieta HF apresentaram um aumento de gordura total e visceral. 
 Relativamente ao perfil lipídico, as dietas hipercalóricas não produziram alterações 
nos níveis de colesterol total ou de colesterol LDL. Contudo, após as dietas, os níveis de 
colesterol HDL encontravam-se diminuídos nos animais HF. Para além disso, ambas as dietas 
hipercalóricas provocaram um aumento nos níveis de triglicéridos, mas apenas a dieta rica 
em sacarose induziu um aumento nos ácidos gordos livres.  
 Tal como esperado, observou-se que em ambos os modelos patológicos de insulino-
resistência ocorreu uma diminuição na expressão do recetor de insulina e na expressão de 
Glut4, no músculo-esquelético. O mesmo não se observou na expressão de Glut2 no fígado 
onde apenas a dieta HF levou a uma diminuição da mesma.  
 A resseção do nervo do seio carotídeo e consequente supressão da atividade do corpo 
carotídeo restaurou completamente a sensibilidade à insulina e também os níveis de glicémia 
em jejum e de insulina plasmática. Para além disso, impediu o aumento de peso, nos ratos 
submetidos às dietas hipercalóricas, levando a uma diminuição na quantidade de gordura 
visceral e total, e a uma melhora do perfil lipídico. Adicionalmente, a desnervação do corpo 
carotídeo restaurou, também, os níveis de expressão do recetor de insulina e do transportador 
de glucose Glut4, no músculo-esquelético, e do transportador de glucose Glut2, no fígado.  
 Em conclusão, este estudo demonstra que a supressão da atividade do corpo 
carotídeo poderá ser utilizada como uma possível intervenção terapêutica, o que destaca a 
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importância de desenvolver estratégias de forma a reduzir a sobreactivação do corpo 
carotídeo nas doenças metabólicas. 
 
Palavras-chave: corpo carotídeo, diabetes mellitus tipo 2, resistência à insulina, 
resseção do nervo do seio carotídeo, síndrome metabólica 
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1 Introdução 
1.1 Diabetes Mellitus  
 
Metabolic disorders like obesity, insulin resistance (IR), hyperglycemia, hyperlipidemia 
and hypertension (HT) clustered together have been described as the “insulin resistance 
syndrome” (Reaven, 1988; Moller and Kaufman, 2005). However, nowadays, the term 
“metabolic syndrome” has been adopted (Reaven, 1988; DeFronzo and Ferrannini, 1991; 
Kahn et al., 2005) and metabolic syndrome has become one of the major public-health 
challenges worldwide. Also, metabolic syndrome is a major risk factor for both cardiovascular 
dysfunction and diabetes mellitus (Albertini et al., 2005). 
In the past two decades, there has been an increase in the number of people diagnosed 
with diabetes all over the world (Zimmet et al., 2001). In fact, it was estimated that in 2010 the 
number of people with diabetes was approximately 285 million and that in 2030 will increase 
to 439 million (Shaw et al., 2010). In the Portuguese population, it is estimated that about 
34.5% (between the ages of 20 and 79 years) have diabetes or pre-diabetes and 44% of 
people with diabetes are unaware of their condition (Gardete-Correia et al., 2010). Taking into 
account this epidemic, there is of great interest identify and implement interventions to prevent 
or delay its onset.  
According to the American Diabetes Association, the classification of diabetes includes 
four clinical classes: Type 1 Diabetes, Type 2 diabetes mellitus (T2DM), Gestacional Diabetes 
Mellitus and other specific types of diabetes duo to other causes (Serrano-Ríos, Reviriego and 
Fuentes, 2010) 
T2DM is a complex polygenic pathology characterized by the presence of defects in 
both insulin secretion (beta-cell dysfunction) and insulin action (Kashyap and DeFronzo, 2007).  
  
Figure 1 – Natural history of type 2 diabetes (T2DM). The earliest detectable abnormality in T2DM is a reduction 
in the body's ability to respond to insulin, called insulin resistance (IR). At this point the pancreas is able to 
appropriately augment insulin secretion to normalize glucose levels in plasma, and therefore this phase called 
prediabetes is characterized by normoglycemia and hyperinsulinemia. With time, however, the β-cell is no longer 
able to maintain its high rate of insulin secretion leading to the development of impaired glucose tolerance (IGT) 
and eventually over time diabetes mellitus. (Adapted from Internacional Diabetes Center, Minneapolis) 
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1.2 Insulin and insulin action 
Insulin is a 51 amino acids peptide hormone, organized in 2 polypeptide chains, A and B, 
of 21 and 30 amino acids, respectively, connected by disulphide bridges. Insulin is synthesized 
and release by β-pancreatic cells being central in regulation of carbohydrate and fat 
metabolism in the body. In insulin sensitive tissues, like skeletal muscle and fat tissue, insulin 
binds to its specific receptor, the insulin receptor inducing the uptake of glucose from the blood 
(Kahn and White, 1988).  
The insulin receptor is a glycoprotein that belongs to a subfamily of receptor tyrosine 
kinases and consists of extracellular α- and transmembrane β-subunits. Due to its action as 
allosteric enzyme, the α-subunit inhibits tyrosine kinase activity of the β-subunits (Saltiel and 
Kahn, 2001; Guo, 2014). When insulin binds to the α-subunit of its receptor, the net effect is 
the dimerization of the receptor to form a complex, α2β2, in the cell membrane and 
autophosphorylation of the β-subunit at Tyr1158, Tyr1162 and Tyr1163 which leads to insulin 
receptor activation. Insulin receptor tyrosine kinase activation recruits and phosphorylates 
several substrates like insulin receptor substrates 1-4 (IRS1-4), SHC-adaptor protein, growth 
factor receptor-bound protein 2 (Grb-2-associated protein), dedicator of Cytokinesis 1 
(DOCK1), CBL and APS adaptor proteins, providing specific docking sites for recruitment of 
downstream signalling proteins and leading to activation of both signalling cascades, Ras 
Mitogen-activated protein kinase (MAPKs) and phosphatidylinositide-3-kinase (PI3K)Protein 
kinase B (Akt) (Guo, 2014). RasMAPKs activation mediates the effect of insulin on 
mitogenesis and cell growth whereas PI3K activation generates phosphatidylinositol (3,4,5)- 
triphosphate (PIP3) that will activate 3-phosphoinositide protein kinase 1 and 2 (PDK1 and 
PDK2), which mediate the insulin effect on metabolism and pro-survival (Guo, 2014). PDK1 
and PDK2 are crucial for protein kinase B (Akt/PKB) activation, by inducing phosphorylation at 
T308 and S473, respectively (Guo, 2014).  
Akt/PKB phosphorylates several downstream targets including: i) glycogen synthase 
kinase 3p (Gsk3b) which is phosphorylated and inhibited and, in turn, will dephosphorylate and 
activate glycogen synthase (GS); ii) tuberous sclerosis complex 2 (TSC2) which is inhibited, 
thereby activating GTP-binding protein Rheb (RhebGTPase) for the activation of mammalian 
target of Rapamycin complex 1 (mTORC1) and S6K, which promotes protein synthesis; (Guo, 
2014) iii) Akt substrate of 160 kDa (AS160) which will activate Rab10GTPase, leading to 
glucose transporter type 4 (GLUT4) translocation to the plasma membrane allowing glucose 
uptake; iv) BCL2-associated agonist of cell death (Bad), for inhibition of apoptosis; and v) 
phosphodiesterase 3B (PDE3B) for cyclic adenosine monophosphate (cAMP) degradation. 
Also, Akt phosphorylates and inhibits cAMP response element-binding protein (CREB)-
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regulated transcription coactivator 2 (CRTC2), that increases hepatic gluconeogenesis and 
phosphorylates sterol regulatory element-binding protein 1 (Srepb1), promoting liver 
lipogenesis (Wang et al., 2010). On the other hand, Akt/PKB phosphorylates Forkhead box 
protein O1 (Foxo1), inhibiting its transcriptional activity leading to a supressed liver glucose 
production and promoting cell survival in the heart (Guo, 2014).   
 
 
 
 
 
 
 
 
1.3 Glucose homeostasis  
Among nutrients, glucose is the major source of fuel for energy metabolism thus, 
glucose homeostasis is ensured by a balance between glucose absorption from the intestine, 
production by liver, and uptake and metabolism by the peripheral tissues (Saltiel and Kahn, 
2001). 
In normal individuals, plasma glucose remains between values of 4 and 7 mM (despite 
periods of feeding and fasting). During fasting (10 to 12h overnight fast) the majority of total 
body glucose disposal takes place in insulin-independent tissues. Approximately 50% is used 
by the brain, 25% by the liver and gastrointestinal tissues, and the remaining 25% is used by 
insulin-dependent tissues, primarily muscle, and in a lesser extent by the adipose tissue. 
Approximately 85% of endogenous glucose production is derived from the liver, the remaining 
15% is produced by the kidney and, both glycogenolysis and gluconeogenesis contribute 
equally to the basal rate of hepatic glucose production (DeFronzo, 2004).  
Figure 2- Insulin signaling pathways, where is represented insulin receptor and molecules involved in insulin action. 
(more details in the text above) (Adapted from Saltiel and Kahn, 2001)  
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After glucose ingestion, the increase in 
plasma glucose concentration stimulates 
insulin release by pancreatic β-cells. 
Increments in insulin plasma concentration 
inhibit lipolysis, leading to a decline in the 
plasma level of free fatty acids (FFA). This 
decline leads to an increase on muscle 
glucose uptake and contributes to the 
inhibition of hepatic glucose production. 
(Saltiel and Kahn, 2001; Boden and 
Shulman, 2002; DeFronzo, 2004). 
Glucagon also plays a central role in 
glucose homeostasis regulation. During fasting conditions, approximately half of total hepatic 
glucose output is dependent on the maintenance of normal basal glucagon levels. On the other 
hand, after ingestion of a glucose-containing meal, glucagon secretion is inhibited contributing 
to hepatic glucose production repression (DeFronzo, 2004). 
 
1.4 Alterations in insulin action and glucose homeostasis in metabolic disorders 
1.4.1 Insulin resistance  
Insulin resistance (IR) occurs when the insulin-sensitive tissue loss the response to 
insulin (Ye, 2013). Although the mechanisms that lead to the appearance of IR remain 
unknown, several factors have been proposed to explain this mechanism, among which are 
highlighted: obesity, inflammation, hyperinsulinemia, lipotoxicity/hyperlipidemia, stress, aging, 
fatty liver and hypoxia (Ye, 2013). 
 The vast majority of these factors are associated with obesity and aging, which are the 
major risk factors for IR in the population (Ye, 2013).  
 Obesity is characterized by a proinflammatory state that starts in adipose tissue and 
liver with elevated macrophage infiltration and expression of proinflammatory cytokines. 
Inflammation inhibits the insulin signalling activity in adipocytes and hepatocytes through 
several mechanisms: i) inhibition of IRS-1 and insulin receptor in the insulin signalling pathway 
(White, 2002; Ye, 2011); ii) inhibition of peroxisome proliferator-activated receptor gamma 
(PPARγ) function (PPARγ drives lipid synthesis and fat storage in cells) (Ye, 2008; Ye, 2011); 
iii) increase of FFA through lypolisys stimulation and blocking triglycerides (TG) synthesis (Ye, 
2013).   
 Obese adipose tissue mainly releases proinflammatory cytokines among which are 
TNF-α, IL-6, leptin, and adiponectin. TNF-α induces IR directly (by IRS-1 phosphorylation) 
Figure 3 –Glucose Homeostasis (Adapted from Wardlaw 
et al., 2007) 
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(Kanety et al., 1995) and indirectly (by altering adipocyte differentiation and adipocyte lipid 
metabolism). Also, TNF-α promotes lipolysis and secretion of FFAs to the plasma, inhibits the 
conversion of pre-adipocytes to mature adipocytes (by downregulating adipogenic genes such 
as PPARγ and CCAAT/enhancer binding protein) (Xu et al., 1999; Makki et al., 2013), and can 
reduce GLUT4 gene expression (Kahn, 2000). IL-6 increases IR by upregulating SOCS3 which 
decreases insulin-induced IRS-1 phosphorylation (Senn et al., 2003).  Also, it can promote 
dysregulation of white adipose tissue  fatty acid metabolism inhibiting adipogenesis (Pricola et 
al., 2009) and it stimulates lipolysis, increasing FFA levels and body fat oxidation (van Hall et 
al., 2003). Leptin is primarily secreted by adipocytes being a key contributor to energy 
metabolism (Friedman, 1998). Leptin acts in the brain, directly or indirectly, by activation of 
specific centers in hypothalamus to decrease food intake, increase energy expenditure, 
influence glucose and lipid metabolism or alter neuroendocrine function (Makki et al., 2013). It 
is known that leptin levels are increased in obese subjects and preclinical and clinical studies 
showed that obese rodents and humans present leptin resistance that may contribute to lipid 
oxidation reduction in insulin-sensitive organs and thus contributing to lipids accumulation and 
IR. However, the mechanisms behind leptin resistance and their role it on IR is still not totally 
understood (van den Hoek et al., 2008; Makki et al., 2013). On the other hand adiponectin, an 
hormone secreted by adipose tissue, is reduced in obesity (Arita et al., 1999). This hormone 
has important insulin sensitizing effect, as showed by studies that have linked plasma 
adiponectin levels to insulin sensitivity in humans and in rodent models (Berg et al., 2002).  
 
 As already mentioned, the relationship between IR and overall obesity is well 
established although it remains unclear which are the fat depots, visceral adipose tissue (VAT) 
or subcutaneous adipose tissue (SAT) that contribute more for this relationship. Several 
studies have demonstrated that there is a strong independent relationship between both VAT 
and SAT and IR, and that visceral fat accumulation decrease peripheral insulin sensitivity and 
enhance hepatic gluconeogenesis, being a more potent predictor of IR than SAT (Gastaldelli 
et al., 2002; Wagenknecht et al., 2003). On the other hand, Abate and colleagues found that 
SAT was more strongly associated with IR, in male patients with T2DM (Abate et al., 1996). It 
seems, however, that the deeper layer of SAT has an association with IR that is similar to the 
pattern for VAT whereas the superficial layer has a weaker association (Kelley et al., 2000). In 
addition to the accumulation of visceral fat and skeletal muscle IR, adipose tissue also presents 
IR, characterized by increased plasma FFA levels. This increased FFA levels are not 
supressed as normally because fat cells are resistant to the antilipolytic effect of insulin, 
resulting in chronically elevated plasma FFA (Bays et al., 2004). It is now consensual that 
plasma FFA are a major contributor of the IR syndrome according to the “overflow hypothesis”, 
which says that once the capacity of adipocyte to store TG is exceeded occurs an overflow 
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and, consequently, accumulation of FFA as long-chain fatty acyl CoAs in the muscle and liver, 
leading to NFkB activation from the nucleus, initiating inflammatory pathways including 
cytokines and growth factor production that interfere with insulin signalling, resulting in IR 
(Bays et al., 2004; Kashyap et al., 2007) 
Another aspect that has been studied and related to IR is hyperinsulinemia. 
Hyperinsulinemia consists of increased levels of plasma insulin in fasting conditions being 
derived from the overproduction or decreased clearance of insulin in the body. Independently 
of which appears first, hyperinsulinemia by itself appears to contribute to perpetuate the IR 
(Shanik et al., 2008). In fact, in vivo, administration of high doses of insulin, reflecting, can 
cause IR (Shanik et al., 2008).  Rizza et al., (1985) demonstrated that after 40 hours of insulin 
infusion, which elevated plasma insulin to levels similar to those found in states of IR, insulin-
stimulated glucose utilization was significantly decreased. Also, one of the characteristics of 
hyperinsulinemic states is an increased level of inflammatory markers, including cytokines and 
C-reactive protein which, as already discussed early in this chapter, can induce IR (Shanik et 
al., 2008).  
 
1.4.2 Impaired glucose tolerance  
Impaired glucose tolerance (IGT) represents an intermediate state of abnormal glucose 
regulation, occurring between normal glucose homeostasis and diabetes (Nathan et al., 2007).  
Studies have provided quantitative evidence that progression to glucose intolerance is 
associated with the development of IR. Therefore, early in the history of T2DM, IR is 
established but glucose tolerance remains normal (DeFronzo, 1992; DeFronzo 2007). As the 
fasting plasma glucose rises from 80 to 140mg/dL, the fasting plasma insulin concentration 
increases, reaching a value 2.0 to 2.5-fold higher than in non-diabetic individuals with normal 
weight and, when the fasting plasma glucose exceeds 140mg/dL, the beta cell is no longer 
able to maintain its elevated rate of insulin secretion and the fasting insulin concentration 
decreases progressively, resulting in IGT (DeFronzo., 2004). Therefore, IGT is defined as a 2-
h serum glucose level between 140 and 199 mg/dl, during an oral glucose tolerance test 
(OGTT) (Krentz., 1996).   
The progression from IGT to T2DM is heralded by β-cell failure to maintain its 
previously rate of insulin secretion in response to high values of glucose (DeFronzo., 2004). 
 
1.4.3 Dyslipidemia  
It is known that dyslipidemia is strongly associated with metabolic diseases, like T2DM 
being an elevated risk for coronary heart disease (CHD) (Mooradian, 2009; Klop et al., 2013) 
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The typical dyslipidaemia in T2DM can include the various types of dyslipidaemia 
identified in the general population. However, the core components of diabetic dyslipidaemia 
are increased fasting and postprandial plasma TG and FFA, low levels of high density 
lipoprotein cholesterol (HDL-C)  (with HDL-C dysfunction) and normal or slightly increased low 
density lipoprotein cholesterol (LDL-C) with increased concentration of small dense LDL-
cholesterol particles (SD LDL) (Mooradian, 2009; Wang and Peng, 2011; Klop et al., 2013) 
 
The exact pathogenesis of T2DM dyslipidaemia is not known but there are evidences 
suggesting that IR has a central role in its development. The main cause of the features of 
diabetic dyslipidaemia is the increased FFA release from insulin-resistant fat cells (Frayn, 
2001). The increased flux of FFA into the liver, in the presence of glycogen stores, promotes 
TG production leading to the secretion of apolipoprotein B (ApoB) and very low-density 
lipoprotein (VLDL) cholesterol. The decreased ability of insulin to inhibit FFA release leads to 
enhanced hepatic VLDL cholesterol production (Frayn, 2001; Taskinen, 2003; Mooradian, 
2009). Therefore, the increased number of VLDL cholesterol particles and the increased levels 
of TG decrease the HDL-C levels and increase the concentration of SD LDL particles through 
multiple processes (See figure 4) (Mooradian et al., 2004; Mooradian et al., 2008).  
  
Figure 4 - Role of insulin resistance (IR) in type 2 diabetes mellitus (T2DM) dyslipidaemia. Insulin resistant cells 
release free fatty acids (FFA) leading to an increased flux of FFA into the liver which promotes triglyceride (TG) 
production and secretion of apolipoprotein B (ApoB) and very low-density lipoprotein cholesterol (VLDL). 
Cholesteryl ester transfer protein (CETP) promotes the exchange from VLDL- transported triglyceride to high-
density lipoprotein (HDL)-transported cholerteryl ester (CE), which results in increased amounts of both atherogenic 
cholesterol-rich VLDL remnant particles and triglyceride-rich, cholesterol-depleted HDL particles.(Adapted from 
Mooradian, 2009) 
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1.5 Carotid Body  
In cases of acute hypoxia, mammals need rapid respiratory and cardiocirculatory 
adjustments to guarantee that oxygenated blood can reach their tissues and their brain cells 
(López-Barneo, 2003; Peers et al., 2010). The main chemoreceptors that are able to detect 
alterations in blood gases and pH are the carotid bodies (CB) (López-Barneo, 2003). 
The CB’s are small paired organs located at the bifurcation of the common carotid arteries 
that are innervated by nerve fibres from the glossopharyngeal (carotid sinus nerve), vagal, and 
the sympathetic nerve of the nearby superior cervical ganglion (González et al., 1995; Kumar, 
2007; Paton et al., 2013). The CB’s receive blood via an arterial branch arising from internal 
or external carotid artery and are composed by two type of cells, type I cells (also called 
chemoreceptor cells or glomus cells) and type II cells (also called sustentacular cells) 
(Iturriaga, 2004). Type I cells are of neural crest origin and possess dark, as well as clear, 
cored vesicles and type II cells are similar to the glial cells of the nervous system (Prabhakar, 
2000; Paton et al., 2013). (see figure 5).  
 
 
 
 
 
 
 
 
 
When CB’s are activated by hypoxia and or by acidosis or hypercapnia they respond by 
increasing the action potential frequency in their sensory nerve, the carotid sinus nerve (CSN). 
Then, CSN activity is integrated in the brain stem to induce a fan of respiratory reflexes aimed, 
primarily, to normalize the altered blood gases via hyperventilation and to regulate blood 
pressure and cardiac performance via sympathetic nervous system activation (Gonzalez et al., 
1994).  Also, the CB directly activates the adrenals via an increased sympathetic drive and 
also increases sympathetic vasoconstrictor outflow to muscle, splanchnic, and renal beds 
(Marshall et al., 1994). Apart from its role in the control of ventilation, the CB has been 
C 
Figure 5 - Drawing of the carotid artery bifurcation (A) and a cellular cluster of the carotid body (B); and a 
histological image of a slice of 10 µM of the carotid body (C). In A the common carotid artery (1) that divides to 
internal (2) and external (3) arteries. Sensory fibres originated in petrosal ganglion (5) reach the carotid body (4) 
via carotid sinus nerve (CSN) (6). The superior cervical ganglion (7) also innervates the carotid body, via the 
ganglioglomerular nerves (8).The nodose ganglion (9) is located externally to the internal carotid artery. B Cluster 
of parenchymatous cells of the carotid body, which are formed by chemoreceptor cells (1) that are partially 
surrounded by sustencular cells (2). Sensory nerve endings (4) are in contact with chemoreceptor cells. The 
clusters are surrounded by a dense net of capillaries (6). C Immunohistochemical image of a 10 µM section of the 
CB. (Adapted from Gonzalez et al., 1992) 
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proposed as a glucose sensor being implicated in the control of energy homeostasis (Koyama 
et al., 2000, (Koyama et al., 2000; Pardal and Lopez-Barneo, 2002; Zhang et al., 2007). 
However, the effect of hypoglycaemia on the CB is not consensual, as several authors have 
reported that low glucose did not affect the release of catecholamines from the intact CB and 
CSN frequency of discharges (Bin-jaliah et al., 2004; Conde et al., 2007, Gallego-Martin et al., 
2012).  Also recently, it has been demonstrated that insulin activates the peripheral 
chemoreceptors located at CB (Ribeiro et al., 2013) and probably hyperinsulinemia will 
originate the overactivation of the CB contributing to the increased sympathetic nervous 
system activity starting a cycle that leads to decreased peripheral insulin action and 
hypertension (Ribeiro et al., 2013). In fact, Ribeiro et al., 2013 have demonstrated that CB 
overactivity is present in animal models of IR and HT and that a bilateral resection of CSN 
prevents the development, not only of IR and HT induced by diet, but also of increased fasting 
plasma glucose, fasting plasma insulin, FFA, and systemic sympathoadrenal overactivity, 
meaning that CB plays a role in the regulation of whole body insulin sensitivity.  
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2 Aims 
Taking into account the urgent need to find new therapeutic targets that can be used 
to metabolic disturbances, as T2DM and metabolic syndrome and knowing that this 
disturbances are associated with an increased CB activity and consequent increase in the 
sympathetic nervous system activity, the main goal of this project was to investigate the 
abolishment of CB activity as a potential therapeutic intervention to reverse IR and HT. 
The specific aims of this project are: 
- Investigate if CSN resection restores insulin sensitivity and hyperinsulinemia in 
animal models of prediabetes and metabolic syndrome 
- Investigate the effect of CSN resection on weight gain, fat distribution and lipid 
profile in models of prediabetes and metabolic syndrome 
- Study the molecular mechanisms by which CSN resection have a beneficial effect 
on metabolic and cardiovascular parameters. 
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3 Methods  
 
3.1 Animals and experiments 
Experiments were performed in Wistar rats (200–420 g) of both sexes, aged 3 months 
and obtained from the vivarium of Faculty of Medical Sciences.  
Two pathological animal models were used: the high-fat (HF) model which combines 
obesity, IR and HT (Shearer et al., 2009; Conde et al., 2012) and the high-sucrose (HSu) model 
which is a lean model of IR and HT (Ribeiro et al., 2013; Conde et al., 2012).  
Rats were submitted to hypercaloric diets in order to induce T2DM and metabolic 
syndrome. Therefore, the HSu model was achieved by administration of 35% sucrose (Panlab, 
Portugal) in drinking water during 28 days and the HF model was kept under a lipid rich diet 
(45% fat+35% carbohydrate+20% protein, Mucedola, Italy) during 21 days. The control group 
fed a standard diet (7.4% fat+75% carbohydrate (4% sugar)+17% protein, SDS diets RM1, 
Probiológica, Portugal). 
After diets, IR was confirmed by an insulin tolerance test (ITT) and, after that, the 
animals were submitted to bilateral CSN resection under ketamine (30mg/kg)/xylazine 
(4mg/kg) anaesthesia and brupenorphine (10µg/kg) analgesia. The control groups were 
submitted to a sham procedure.  
Caloric and liquid intake were monitored daily, before and after the surgical procedures 
in all groups of animals. Body weight and animal behavioural changes were assessed twice 
per week.  
After the surgical procedure the animals were kept under the respective diets and 
fasting glucose, insulin sensitivity and body weight were evaluated weekly.  
When insulin sensitivity was restored to control values in the Hsu and HF rats submitted to 
CSN cut, the animals were anaesthetised with pentobarbital (60mg/kg i.p.) and transferred to 
a heating pad to maintain body temperature at 37, 5 ± 0, 5ºC throughout the experiment. CSN 
resection was confirmed through the absence of ischemic hypoxia-induced hyperventilation 
assessed as occlusion of common carotid artery (Monteiro et al., 1989; Ribeiro et al., 2013).  
Blood was collected and treated for quantification of plasma insulin and evaluation of lipid 
profile. Also, visceral fat and total fat were collected after an abdominal laparotomy and 
weighted, and tissues were collected and frozen at -80ºC.  
Principles of laboratory care were followed in accordance with the European Union 
Directive for Protection of Vertebrates Used for Experimental and Other Scientific Ends 
(2010/63/EU). Experimental protocols were approved by the Ethics Committee of the Faculty 
of Medical Sciences. 
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3.2 Insulin tolerance test  
The insulin tolerance test (ITT) provides an estimate of overall insulin sensitivity and 
consisted of the administration of an intravenous insulin bolus of 0·1U (4·5 mg)/kg body weight, 
followed by the measure of the decline in plasma glucose concentration over 15 min at 1 min 
intervals. Before this test was performed, the animals were kept under an overnight fast and 
post-food-deprivation body weights were used to calculate insulin doses. Blood was drawn via 
tail tipping and glucose levels were measured with a Glucose Analyzer (Kinzig et al., 2010; 
Conde et al., 2012).   
The constant rate for glucose disappearance (KITT) was calculated using the formula 
0·693/t1/2. Glucose half-time (t1/2) was calculated from the slope of the least-square analysis 
of plasma glucose concentrations during the linear decay phase (Ribeiro et al., 2013; Conde 
et al., 2012).   
 
3.3 Measurement of plasma insulin and circulating free fatty acids 
After the experiments, blood and serum was collected, by cardiac puncture, to EDTA 
coated tubes and Eppendorfs respectively. Plasma samples were centrifuged (Sigma, Madrid, 
Spain) during 10 minutes at 3000g (4ºC) and serum samples were centrifuged (Eppendorf, 
Madrid, Spain) during 10 minutes at 13000g (4ºC). 
Insulin concentrations were determined in plasma with an ELISA kit (Mercodia 
Ultrasensitive Rat Insulin ELISA kit; Mercodia AB, Uppsala, Sweden) and circulating FFA were 
determined in plasma, with an ELISA kit (96-well Serum/Plasma Fatty Acid kit for detection of 
non-esterified fatty acids; Zen-bio, North Carolina).  
 
3.4 Lipid profile evaluation 
Lipid profile was assessed in plasma using a RANDOX kit (RANDOX, Irlandox, Porto, 
Portugal) that evaluates total cholesterol and TG by Trinder-based colorimetric end-point 
assays, and HDL and LDL by a direct-HDL and direct-LDL clearance methods, respectively.  
 
3.5 Western Blot 
3.5.1 Western Blot analysis of insulin receptor and glucose transporter Glut4 protein 
expression in skeletal muscle  
Samples of skeletal muscle (50 mg) were homogenized in Zurich (10mM Tris-HCl, 1mM 
EDTA, 150mM NaCl, 1% Triton X-100, 1% sodium cholate, 1% SDS) with a cocktail of 
protease inhibitors (trypsin, pepstatin, leupeptin, aprotinin, sodium orthovanadate PMSF), and 
centrifuged (Eppendorf, Madrid, Spain) at 13000g for 20minutes.  
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After centrifugation, the supernatant was collected and frozen at -80ºC until further use. 
The protein concentration of the homogenates was determined by a Micro-BCA colorimetric 
assay (Pierce, Madrid, Spain). Homogenate samples (50µg) and known molecular weight 
markers (Precision, Biorad, Madrid, Spain) were separated by SDS-PAGE (10%) under 
reductive conditions. 
After samples separation by SDS-PAGE, they were electroblotted onto polyvinylidene 
difluoride membranes (PVDF) (0.45µM, Millipore, Spain). Then, nonspecific binding was 
blocked by incubating the membranes with a solution of 5% milk powder in Tris buffer saline 
(TBS), pH 7.6 containing Tween 20 (TTBS 0.1%) (BioRad, Spain), for 1 hour at room 
temperature. The membranes were, then, incubated overnight at 4°C with primary polyclonal 
goat anti-Glut4 antibody (1:200) (Santa Cruz Biotechnology, USA) and primary polyclonal 
mouse anti-IR antibody (1:200) (Santa Cruz Biotechnology, USA).   
After 3 washes of 15 min with TTBS (0.1%), membranes were incubated for 90 min with 
secondary mouse anti-goat antibody (1:5000) (Santa Cruz Biotecnhology, USA) at room 
temperature. Following washing of secondary antibody, the membranes were incubated with 
a chemiluminescence reagent (ClarityTM Western ECL substrate, BioRad, United States) for 
detection of the protein of interest. Signal intensity was detected in Chemidoc Molecular 
Imager (BioRad Chemidoc, Spain).  
  Then IR membranes were washed and incubated for 2 hours at room temperature with 
polyclonal mouse anti-α-tubulin (1:200) and Glut4 membranes were washed and incubated for 
2 hours at room temperature with mouse monoclonal anti-GAPDH antibody (1: 250) (Santa 
Cruz Biotecnhology, USA). After 3 washes of 15 min with TTBS (0.1%), membranes were 
incubated for 90 min with the secondary antibody goat anti-mouse (1:5000 and 1: 2000) (Santa 
Cruz Biotecnhology, USA), respectively for IR and Glut4. The incubation with α-Tubulin and 
GAPDH allow normalization of the bands and the comparison of the expression of insulin 
receptor and Glut4 proteins to the reference protein, α-Tubulin and GAPDH, respectively.  
 
3.5.2 Western Blot analysis of glucose transporter Glut2 protein expression on liver 
Samples of liver (100 mg) were homogenized in Blys solution (100 mM Tris-HCL pH7.5, 
0.2mM EGTA pH8, 0.2mM EDTA pH8, 1% Triton X-100 and 0.27M Sucrose) with a cocktail of 
protease inhibitors (trypsin, pepstatin, leupeptin, aprotinin, sodium orthovanadate PMSF), and 
centrifuged (Eppendorf, Madrid, Spain) at 13000g for 20minutes.  
After centrifugation, the supernatant was collected and frozen at -80ºC until further use. 
The protein concentration of the homogenates was determined by a Micro-BCA colorimetric 
assay (Pierce, Madrid, Spain). Homogenate samples (50µg) and known molecular weight 
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markers (Precision, Biorad, Madrid, Spain) were separated by SDS-PAGE (10%) under 
reductive conditions. 
After samples separation by SDS-PAGE, they were electroblotted onto polyvinylidene 
difluoride membranes (PVDF) (0,45µM, Millipore, Spain). Then, nonspecific binding was 
blocked by incubating the membranes with a solution of 5% milk powder in Tris buffer saline 
(TBS), pH 7.6 containing Tween 20 (TTBS 0.1%) (BioRad, Spain), for 1 hour at room 
temperature. The membranes were, then, incubated overnight at 4 ° C with primary polyclonal 
goat anti-Glut2 antibody (1: 200) (Santa Cruz Biotechnology, USA). After 3 washes of 15 min 
with TTBS (0.1%), membranes were incubated for 90 min with secondary donkey anti-goat 
antibody (1: 2000) (Santa Cruz Biotecnhology, USA) at room temperature. Following washing 
of secondary antibody, the membranes were incubated with a chemiluminescence reagent 
(ClarityTM Western ECL substrate, BioRad, United States) for detection of the protein of 
interest. Signal intensity was detected in Chemidoc Molecular Imager (BioRad Chemidoc, 
Spain).  
After detection, Glut2 membranes were washed and incubated for 2 hours at room 
temperature with mouse monoclonal anti-GAPDH antibody (1: 250) (Santa Cruz 
Biotecnhology, USA). After 3 washes of 15 min with TTBS (0.1%), membranes were incubated 
for 90 min with the secondary antibody goat anti-mouse (1: 5000) (Santa Cruz Biotecnhology, 
USA). GAPDH incubation allows normalization and comparison of the expression of Glut2 
proteins to the reference protein.  
 
3.6 Data analysis  
Data were assessed with Graph Pad Prism Software, version 4 (GraphPad Software 
Inc., San Diego, CA, USA) and presented as mean values with their standard errors. The 
significance of the differences between the mean values was calculated by one- and two-way 
ANOVA with Dunnett’s and Bonferroni multiple comparison tests, respectively. Differences 
were considered significant at P<0·05. 
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4 Results  
 
4.1 Effect of carotid sinus nerve resection on glycemia  
 
Figure 6 shows the effect of chronic CSN denervation on fasting glycemia in hypercaloric 
animal models of IR, the HSu and HF model.  CSN resection did not modify fasting glycemia 
in control and HF animals (Fig. 6A and C). However, HSu diet increased significantly by 48.7% 
fasting glycemia as previously described (Conde et al., 2012; Ribeiro et al., 2013), an effect 
that was totally reversed by CSN resection, as one week after the surgical procedure glycemia 
value was similar to control (control = 83.3±1.8 mg/dl; HSu one week after CSN resection = 
83.1±4.3 mg/dl), remaining within two weeks later (Fig. 6B). 
 
 
  
 
 
 
 
 
 
 
4.2 Effect of carotid sinus nerve resection on insulin sensitivity 
In figure 7 is represented the effect of CSN ressection on insulin sensitivity. Insulin 
sensitivity was determined by the insulin tolerance test and was not affected by CSN 
denervation in control animals (figure 7A). HSu and HF diets decreased insulin sensitivity by 
47.0 and 40.1% from a control value of KITT = 4.39±0.94 % glucose/min, respectively (figure 
7B and C).  
 IR was partially reversed one week after CSN denervation in HSu and HF animals. Two 
weeks after CSN denervation IR was totally reversed and this effect was maintained at the 
third week after CSN resection (figure 7B and C).  
 
Figure 6 - Effect of carotid sinus nerve (CSN) denervation on fasting plasma glucose in control (A), high-sucrose 
(HSu) (B) and high-fat (HF) (C) diet rats, respectively. White bars represent values of fasting plasma glucose in 
control animals without (CSN) denervation. Colour bars represent values of glycemia in rats before and after CSN 
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4.3 Effect of carotid sinus nerve resection on plasma insulin levels   
Figure 8 illustrates the effect of CSN ressection on plasma insulin levels. Both HSu and 
HF diets increased significantly plasma insulin levels by 55%, producing a markedly increase 
(hyperinsulinemia) from a control value of  1.98±1.31μg/L. Diet-induced hyperinsulinemia was 
totaly reversed by CSN ressection (figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7- Effect of carotid sinus nerve (CSN) denervation on insulin sensitivity determined by the insulin tolerance 
test, expressed as the constant rate for glucose disappearance (KITT) in control, high-sucrose (HSu) and high-fat 
(HF) diet rats, respectively. White bars represent values of insulin sensitivity in control animals without CSN 
denervation. Colour bars represent values of insulin sensitivity in rats before and after CSN denervation. One-Way 
ANOVA with Bonferroni multicomparison tests, respectively; *** p<0.001 vs control; ##p<0.01, ###p<0.001 
comparing values with and without CSN resection. 
Figure 8 - Carotid sinus nerve resection restores plasma insulin levels in the animal models of insulin resistance 
induced by hypercaloric diets, HSu (B) and HF (C). Quantification of plasma insulin was made over three weeks 
after CSN denervation and compared with control, HSu and HF animals not submitted to CSN denervation. Bars 
represent mean  S.E.M. One-Way ANOVA with Bonferroni multicomparison tests, respectively; *** p<0.001 vs 
control; ##p<0.01, ###p<0.001 comparing values with and without CSN resection 
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4.4 Effect of carotid sinus nerve resection on weight variation, total fat, visceral fat 
and lipid profile in diet induced-insulin resistant rats   
After 7 weeks of HSu diet (4 weeks to induce IR + 3 post-CB denervation) and 6 weeks 
of HF (3 weeks to induce IR + 3 post CB denervation), both animal models presented an 
increased weight gain per day than controls rats (Table 1). However, CSN resection prevented 
this weight gain induced by both hypercaloric diets (Table 1).  Only HF exhibited an increase 
in total and visceral fat, which was partially reversed by CSN denervation (Table 1).  
 
 
Table 1- Effect of CSN resection on weight, total fat and visceral fat in control, high fat and high sucrose diet rats. 
Data with and without carotid sinus resection are means of 8-9 and 8-10 values, respectively. 
 
 
Weight refers to the difference between weight measured 3 weeks after CSN denervation and weight immediately 
prior to denervation. One and Two-Way ANOVA with Dunnett’s and Bonferroni multicomparison tests, respectively; 
*p<0.05 and *** p<0.001 vs control; ##p<0.01 and ###p<0.001 comparing values with and without CSN resection 
 
 
In relation to lipid profile neither hypercaloric diets nor CSN resection significantly modified 
total cholesterol and LDL levels (fig. 8A and B). However, HDL levels were diminished by 27% 
in HF animals (control= 27.99±1.21mg/dL; HF=20.33±1.21 mg/dL), and CSN resection partially 
reversed this decrease (C). HSu and HF diets increased TG by 56.1 and 46.0%, respectively 
(control=31.065±3.49 mg/dL), and these values were brought back to control levels after CSN 
resection (D). 
 
 
 
Treatments Control High-Sucrose Diet High-Fat Diet 
 
Without 
CSN 
resection 
With 
CSN 
resection 
Without 
CSN 
resection 
With CSN 
resection 
Without 
CSN 
resection 
With CSN 
resection 
Weight 
gain 
(g/day) 
0.680.2 0.380.2 1.310.1* 0.050.1### 1.430.3* 0.070.3### 
Total fat 
(g/kg) 
51.72.4 47.46.3 47.23.0 51.43.3 70.13.6** 64.76.3 
Visceral fat 
(g/kg) 
9.90.4 9.50.6 10.20.5 9.70.6 13.80.8*** 11.80.9# 
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4.5 Effects of carotid sinus nerve resection in on plasma free fatty acids levels, in diet 
induced-insulin resistant rats   
Figure 10 display the effect of CSN resection on plasma FFA. HSu diet increased plasma 
FFA by 32%, an effect that was absence in animals submitted to HF diet (control = 
575.6±78.9µM; HF = 481.7±73.7 µM; HSu=852.05±141.62 µM).  Surprisingly, CSN resection 
did not modified FFA in controls or in the pathological animal models. 
 
 
 
 
 
 
 
 
Figure 9 - Effect of CSN resection on lipid profile in control, HSu and HF diet rats. Neither hypercaloric diets nor 
CSN resection significantly modified total cholesterol and LDL levels (A and B). However, CSN resection partially 
reversed decreased HDL levels (C) and restored triglycerides levels back to control levels after CSN resection (D). 
Bars represent mean  S.E.M. One and Two-Way ANOVA with Dunnett’s and Bonferroni multicomparison tests, 
respectively; *p<0.05 and *** p<0.001 vs control; ##p<0.01 and ###p<0.001 comparing values with and without 
CSN resection 
Figure 10 - Plasma free fatty acids (FFA) levels in control, HSu and HF animal with and without carotid sinus nerve 
resection. Bars represent mean  S.E.M. One way ANOVA with Bonferroni multicomparison tests, respectively; 
*p<0.05, comparing control and HSu values without CSN resection 
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4.6 Effect of carotid sinus nerve resection on insulin receptor and glucose transporter 
Glut4 protein expression in skeletal muscle  
Figure 11 A and B show representative Western Blots that compare the expression of 
insulin receptor and glucose transporter Glut4 in skeletal muscle, which correspond to 97 and 
54KDa, respectively, in control, HSu and HF animals.  
As we can see in figure 11C and as expected, insulin receptor expression was 
significantly decreased by 51% and by 41%, in HSu and HF animals.  Although, CSN resection 
totally restored insulin receptor expression in the HF model, it was incapable of modify insulin 
receptor expression in the HSu model (control = 100.00±8.56%; HSu = 62.68±10.58%; HF = 
101.43±5.42%). Glut4 expression, presented in figure 10D, was decreased after HSu and HF 
diets (control = 100.00±7.25%; HSu =54.33±6.19%; HF = 92.68±6.37%). However, CSN 
resection totally restored Glut4 expression to control values (control = 100.00±7.25%; HSu 
with CSN resection=96.25±6.50%; HF with CSN resection = 101.57±16.63%).  
 
 
 
 
 
 
 
 
Figure 11 – Effect of carotid sinus nerve (CSN) resection on insulin receptor and glucose transporter Glut4 protein 
expression in skeletal muscle. A) and B) are  representative images of Western Blot  comparing insulin receptor 
(97 kDa) and Glut4 (54 kDa) expression; C) presents  the mean values of the expression of insulin receptor without 
CSN resection (n=5-10) and with CSN resection (n=2-4) in relation to α-Tubulin expression; D) presents the mean 
values of Glut4 expression without CSN resection (n=5-10) and with CSN resection (n=5-6) in relation to GAPDH 
expression. Bars represent mean  S.E.M. One-Way ANOVA with Dunnett multicomparison test, **p<0.01, *** 
p<0.001 vs control; Two-Way ANOVA with Bonferroni multicomparison test, ##p<0.01 comparing values with and 
without CSN resection. 
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4.7 Effect of carotid sinus nerve resection on glucose transporter Glut2 expression in 
the liver 
Figure 12 depicts the effect of CSN resection on Glut2 expression in the liver in controls 
and in insulin-resistant animal models. Panel A shows representative Western Blots for Glut2, 
which corresponds to 62 kDa and for GAPDH, which corresponds to the 37 KDa band, in 
control, HSu and HF animals. As it can be seen HSu diet did not modify Glut2 expression and 
HF diet showed a tendency to decrease (control = 101.70±6.32%; HSu = 107.30±9.26%; HF 
= 93.8±12.42%). CSN resection did not altered Glut2 expression in controls or in HSu animals, 
although it increased significantly by 34% in HF animals. 
 
 
 
 
 
 
  
Figure 12 – Effect of carotid sinus nerve (CSN) resection on Glut2 expression, in the liver in control, HSu and HF 
insulin-resistant animals. A) shows a representative Western Blot of Glut2 expression; B) present  the mean values 
of Glut2 expression without CSN resection (n=5-10) and with CSN resection (n=2-4) in relation to GAPDH 
expression. Bars represent mean  S.E.M. Two-Way ANOVA with Bonferroni multicomparison test, *p<0.05 
comparing values with and without CSN resection. 
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5 Discussion  
In this study it was demonstrated for the first time that CSN resection and the consequent 
abolishment of CB activity completely restores insulin sensitivity, fasting plasma glucose and 
plasma insulin levels in hypercaloric-animal models of IR and HT. Additionally, CSN resection 
was also capable of restore normal body weight preventing weight gain and leading to a 
decrease in total and visceral fat and to a better lipid profile. Furthermore, it was also showed 
that CB denervation restores insulin signalling pathways in skeletal muscle as it normalize 
insulin receptor and Glut4 levels and enhance Glut2 levels in the liver. 
 
In the present work we have seen that HF diet did not modified significantly glycemia 
levels, whereas HSu diet did. These results are in agreement with the previous findings from 
our laboratory where it was observed that 3 weeks of HF diet were incapable of promoting 
hyperglycemia, although 4 weeks of HSu did increased fasting glycemia (Conde et al., 2012; 
Ribeiro et al., 2013). While the increase in fasting glycemia by HSu diet is consensual 
throughout the majority of the studies (Kamgang et al., 2005; Wilson and Hughes 1996; Ribeiro 
et al., 2005; Ebaid et al., 2006), the normoglycemia during HF diet is not. In Kamgang et al., 
(2005) Wistar rats were distributed into three dietary groups and received either a normal diet, 
a HSu diet (carbohydrates 65-70%, fat 25-30%, protein 10-15%) or a HF diet (carbohydrates 
35-40%, fat 50-55%, protein 10-15%) during 4 months. They show that the fasting glycemia 
levels were significantly elevated in the HSu and HF groups, when compared to de control 
group and that it was highly correlated with the food intake in the HSu group (Kamgang et al., 
2005), although in this study the increase in fasting glycemia promoted by HF diet could be 
due to high percentage of carbohydrates in the diet.  
Also, in the present study it was observed that HF and HSu diet, as previously described, 
induced a decrease in insulin sensitivity (Conde et al., 2012; Ribeiro et al., 2013). This IR was 
also consistent with the results described by Nascimento et al., (2008) study, in which Wistar 
rats were distributed into two groups and received either normal or a cycle of hypercaloric diets 
over a 14-week period. Nascimento et al., (2008) observed that the hypercaloric pellet-diet 
cycle promoted IR. Furthermore, Santuré et al., (2002) conducted a study in Male Sprague-
Dawley rats that were randomized to receive a sucrose- or regular rat chow-diet for 4 weeks, 
and they found that sucrose feeding induces IR which is consistent with the results described 
herein.  
The present work demonstrates that both HSu and HF diets produced a markedly 
increase in  plasma insulin levels (hyperinsulinemia), being these results consistent with our 
previous works (Conde et al., 2012; Ribeiro et al., 2013). All together, the results described in 
the present thesis concerning the effects of hypercaloric diets, both HF and HSu,  in the 
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metabolic parameters, like fasting glycemia, insulinemia and insulin sensivity and the previous 
published (Conde et al., 2012, Ribeiro et al., 2013, Guarino et al., 2014) show that these 
metabolic feautures in these animals models are reproductible within groups in our laboratory. 
One of the first papers that described that increased caloric intake led to statistically significant 
increases in fasting plasma insulin (22%), glucose (5%) and triglyceride (30%) levels was the 
one by Olefsky et al., (1975). They also saw that, most of the changes returned to control levels 
during the succeeding 2 weeks of increased caloric intake, although statistically significant 
elevations of fasting plasma glucose (10%), insulin (8%), and cholesterol (15%) levels were 
still seen at the end of the hypercaloric dietary period (Olefsky et al., 1975). The increase in 
plasma insulin levels after hypercaloric diets  was also observed by McDonald et al., (2011), 
in which male rats were fed an HF diet from weaning until 39 weeks, presenting 
hyperinsulinemia that was not sufficient to maintain normoglycemia, resulting in 
hyperglycemia. Also, Oliveira-Júnior et al., (2010) work showed that rats fed with HF diet 
present hyperinsulinemia. The same findings were observed by Khalkhal et al., (2012) in a 
work in which sand rats were exposed to either a low or a high caloric diet and after 9 months, 
pancreatic islets were isolated and incubated in the presence of increasing cytokine 
concentrations. At the end of the high-energy diet, animals were all over-weight, exhibiting IR, 
hyperinsulinemia and normoglycemia or a marked type-2 diabetic state.  
 
It is known that obesity is strongly associated with IR (Ye, 2013) and that hypercaloric 
diets induce weight gain (Conde et al., 2012). Herein we have shown that the both hypercaloric 
diets induce an increase in weight gain, although the gain/day induced by HF diet was 
significantly higher than the obtained with the HSu diet. The increase in body weight with HF 
diet is not new, as several authors have already described it. Bravo et al., (2014) described an 
increase in body weight in rats kept under diet HF diet during 16 weeks. The same results 
were obtained by Burlamaqui et al., (2011), in a study in which 22 rats were distributed equally 
for two groups, GI (fed with standart diet) and GII (fed with hypercaloric and hyperlipid diet). 
After 23 weeks of experiment, weight was greater in GII. In Humans, this relation was studied 
by Koopman et al., (2014) in a work where 36 lean and healthy men were randomized to a 
40% hypercaloric diet for 6 weeks or a eucaloric control diet. The caloric surplus consisted of 
fat and sugar (high-fat-high-sugar; HFHS) or sugar only (high-sugar; HSu) and was consumed 
together with, or between, the three main meals, thereby increasing meal size or meal 
frequency, resulting in increased body mass index (BMI).  All these findings are coherent with 
the results presented in the present work. 
  
Herein, we have also showed that although hypercaloric diets increased weight gain, 
only HF diet has induced an increase in total and visceral fat. This absence of effects of HSu 
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diet on total and visceral fat suggest that increased adipose tissue mass is not contributing to 
IR in this animal model, which is in accordance with previous results by Kanazawa’s group 
(Kanazawa et al., 2003) In addition, we have shown that none of the hypercaloric diets used 
in the present work significantly modified total cholesterol and LDL levels. However, both HSu 
and HF diets increased TG. This increase in the TG levels was already observed by 
Nascimento et al., (2008), where they found that hypercaloric diets promoted obesity and 
dyslipidemia, being the TG levels increased in the HF diet, when compared to controls 
(Nascimento et al., 2008). Akiyama et al., (1996) have also investigated the effects of a HF 
diet by infusing hypercaloric diet (360 kcal/kg body wt./day) or control diet (180 kcal/kg body 
wt./day), through a cannula directly into the stomach of animals, and they found that serum 
levels of triglyceride were significantly elevated in the HF group, when compared to those in 
the control group. Also in relation to lipid profile, in the present work we have observed that 
HDL levels were decreased in the animals fed with HF diet. These results were expected, 
taking into account the results obtained, in humans, by Laakso et al., (1985). Laakso et al., 
(1985), studied serum lipids and lipoproteins in 277 non-insulin-dependent diabetics (NIDDs) 
and in 124 non-diabetic control subjects. From the 277 NIDDs, 88 were treated with diet, 134 
with oral drugs and 55 with insulin and they showed that the diabetics had lower levels of HDL 
and HDL2-c than non-diabetic control subjects and that body mass index had a significant 
negative correlation to HDL-C (Laakso et al.,(1985). Although, the results obtained by us in the 
present work and the findings in humans contrast with the work by Kamgang et al., (2005) in 
which male Wistar rats maintained in a HF diet (carbohydrates 35-40% kcal, fat 50-55% kcal, 
protein 10-15% kcal) or in a HSu diet (carbohydrates 65-70% kcal, fat 25-30% kcal, protein 
10-15% kcal), during 4 weeks showed total HDL and LDL cholesterol levels were significantly 
elevated in the HF diet group whereas the HDL level was significantly lower in the HSu diet 
group. This difference, in relation to the results obtained in the present work, may be due to 
the different times in which the animals were kept under diets, 4 weeks for both HF and HSu 
diet groups in Kamgang et al., (2005) study and 7 and 6 weeks for HSu and HF groups, 
respectively, in the present study. 
 In contrast to the HF diet, the HSu diet increased circulating FFA levels, indicating 
augmented lipolysis or decreased FFA oxidation in the sucrose-fed rats as previously 
described by our laboratory (Conde et al., 2012) and by others  (Delarue and Magnan 2007, 
Cahova et al., 2012). These results may also be due to an increased de novo lipogenesis in 
adipocytes and in the liver in this model, which in combination with IR may lead to enhanced 
lipolysis and systemic FFA (Lewis et al., 2002, Cahova et al., 2012). In fact, Cahova et al., 
(2012) recently find that in male hereditary hypertriglyceridemic rats fed with either a HSu diet 
(70 cal% as sucrose), or a HF diet (70 cal% as saturated fat) that  HSu diet was associated 
with the depression of FFA oxidation in parallel with increased TG secretion and de novo FFA 
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synthesis. In contrast, in the HF diet administered animals the intracellular TG-derived FFA 
were channelled predominantly to the oxidative utilization (ketogenesis) (Cahova et al., 2012). 
Different results were obtained by Sumiyoshi et al., (2006) in which C57BL/6J mice (4 week 
old) were divided into groups and fed with a low-fat low-sucrose  diet (3% fat, 5% sucrose, 
wt/wt), a HF diet (45% fat, wt/wt), and a HSu diet (50% sucrose, wt/wt), for 55 weeks and they 
that the plasma FFA concentration was significantly greater in mice fed the HF diet than in 
those fed the HSu diet and greater in both of those groups than in mice fed the LL diet. The 
different results obtained in the different studies may rely on the time at which the animals were 
kept under their diets, the composition of diets or even in the different animal species in which 
the experiments have been performed. 
 
 Insulin resistance is manifested by a loss of the response of the insulin-sensitive tissue, 
like skeletal muscle, adipose tissue and the liver, to insulin and it is usually characterized by 
deficiencies in insulin signalling pathways (Ye, 2013). In the present work we have evaluated 
the alterations in the expression of insulin receptor and Glut4 in the skeletal muscle, the major 
tissue responsible for peripheral glucose uptake.  We have showed that both hypercaloric diets 
tested in the present work decreased insulin receptor expression, although only HSu diet 
induced a decrease in total Glut4 expression. Several authors have already reported a 
decreased insulin receptor expression in insulin-resistant states, like Iwashita et al., (2002) in 
where they found that male Sprague-Dawley rats submitted to HF diet (45% fat, 35% 
carbohydrate) and high-carbohydrate diet (5% fat, 75% carbohydrate) during 16 weeks present 
a diminished expression of insulin receptors in soleus and gastrocnemius muscles. Herein, we 
also have shown that Glut 4 expression is decreased in Hsu but not in HF animals. These 
results are in agreement with the previous findings of our lab, where animals submitted to 4 
weeks of HSu diet exhibit a decrease in 58% in Glut4 expression but not HF animals submitted 
to 3 weeks of diet (Guarino et al., 2014). Also, Kim et al., (1999) have showed that glucose 
uptake in skeletal muscle is diminished in rats fed with HSu diet, and so the impaired Glut4 
expression seen by us in the present study and in our previous findings (Guarino et al., 2014) 
could explain the impaired glucose uptake. In Chen et al., (2014) study, similar results were 
obtained in Glut4 expression in skeletal muscle and adipose tissue, in C57BL/6J mice fed with 
a HF diet (35% carbohydrate and 45% fat) for 12 weeks. Although, in Kong et al., (2013) work, 
muscle expression of Glut4 protein was markedly reduced in the Sprague-Dawley rats that 
were fed with HF diet (20,1% carbohydrate, 59,8% fat and 20,1% protein) for 8 weeks. Despite 
the different results between studies, the fact that, in the present work, the HF diet did not 
promoted changes on total Glut4 expression does not mean that the number of Glut4 
transporters in plasma membrane, and therefore, responsible for glucose uptake, were not 
reduced. It is known that Glut4 continuously recycles through several membrane systems of 
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adipose and muscle cells and accumulates in sequestration vesicles (GSV) due to very slow 
exocytosis rates in the absence of insulin stimulation (Huang and Czech, 2007). Thus, it is 
possible that decreased insulin signalling in the muscle cells, as seen herein by a decreased 
insulin receptor expression in muscle, induced by the HF diet, prevents Glut4 exocytosis from 
GSV and subsequent translocation of Glut4 to plasma membrane. Furthermore, some studies 
indicated that insulin-resistant rodents exhibit downregulation of total Glut4 expression 
selectively in adipocytes and not in skeletal muscle, although insulin-stimulated glucose 
transport is also impaired in muscle (Shepherd and Kahn, 1999). 
 Herein we have also found that Glut 2 transporter expression was decreased modestly 
in the HF animal models, but not in the HSu animals, and so this reduction can be one of the 
mechanisms contributing to liver-insulin resistance. This decreased expression of Glut2 in the 
liver is consistent with the findings of other authors (Jwa et al., 2012; Gan et al., 2013¸ Yang 
et al., (2012) Choi et al., (2013)). In fact, Jwa et al., (2012) showed that HF diet during 10 
weeks decreased plasma membrane Glut2 protein concentration. Also, Gan et al., (2013) 
observed that Glut2 expression in the liver was down-regulated markedly in animals submitted 
to HF diet group, during 4 and 8 weeks.  
 
One of the most remarkable results of our work is that we have demonstrate here, for 
the first time, that carotid sinus nerve resection is capable of restore insulin sensitivity, fasting 
plasma glucose and plasma insulin levels in hypercaloric-animal models of IR and HT. This 
results are in line with Ribeiro et al., (2013) work, in where it was shown that CSN ressection 
prevents the development of IR and HT induced by hypercaloric diets. Also, we have shown 
herein that the alterations in insulin signalling pathways in insulin senstive tissues induced by 
hypercaloric diets are restored after CSN resection, and therefore this could be one of the 
mechanims contributing to the restore of insulin sensitivity. 
Additionally, we showed that CSN resection was also capable of restore normal body 
weight preventing weight gain and leading to a decrease in total and visceral fat and to a better 
lipid profile.In our previous publication by Ribeiro et al., (2013) we have showed that CSN 
resection prevents the increase in sympathetic nervous system activity seen in hypercaloric-
induced IR states. Also, obesity is associated with increased sympathetic nervous system 
activity accompanied by a blunted sympathetic nervous system reactivity (Van Baak, 2001) 
and according to our results, bilateral CSN cut normalizes SNS reactivity allowing increased 
energy expenditure and weight loss, suggesting that the IR induced by CB overactivation is 
due to a direct stimulation of the sympathetic nervous system.  Therefore, a complete restore 
of sympathetic activity would restore both insulin secretion and insulin sensitivity in insulin-
sensitive tissues, like skeletal muscle, liver and adipose tissue. In fact, we have observed that 
CSN restore insulin receptor and Glut4 expression in skeletal muscle and increase Glut2 
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expression in the liver, these mechanisms contributing to a recovery of insulin sensitivity. 
Although, and since, we have observed extensive effects of hypercaloric diets on weight gain, 
adipose mass and lipid metabolism, the study of the molecular alterations in insulin signaling 
pathways in adipose tissue and the effect of CSN resection on these pathways would 
contribute enormously to the understand of the mechanism behind CSN resection effects. 
In the last couple of years, several reports of non-classical roles of the carotid bodies 
on glucose homeostasis and metabolic regulation have been published, contributing to launch 
the CB as a putative therapeutic target for the treatment of endocrine diseases. Our group has 
been actively involved in the process and recently we described that chronic CB 
overstimulation is implicated in the etiology of diet-induced IR (Ribeiro et al, 2013). That results 
together with the data obtained in the present thesis contributed to strengthen that CB 
blockade/modulation represents a novel and unexploited therapeutic approach for the 
treatment of metabolic diseases.  
Blocking CB activity, therapeutically, has been widely used to treat several diseases. 
Toorop et al., (2009) have reported the denervation of carotid artery as a therapeutic for carotid 
sinus syndrome. Also, in Toorop et al., (2007) study, it was reported carotid denervation as a 
therapeutic for a patient with carotid sinus syndrome accompanied by excessive vomiting. 
Apart for excessive vomiting and carotid sinus syndrome, unilateral CB resection was used to 
treat dyspnoea in asthmatic and chronic obstructive pulmonary disease patients (Nakayama, 
1965; Holton and Wood, 1965) with documented reductions on systolic blood pressure 
(Nakayama, 1965). More recently, Paton and co-workers suggested that ablation of the CB or 
of its afferents can represent a powerful intervention to reduce excessive sympathetic activity 
in neurogenic hypertension and other sympathetic mediated diseases (Paton et al., 2013). In 
the same line of evidence Niewinski et al.(2013) has reported that unilateral carotid resection 
in a 56-year-old male patient with ischemic chronic heart failure (CHF) restored autonomic 
balance and improved exercise capacity and, therefore quality of life , effects that are 
maintained for at least 6 months. 
Besides the surgical resection of the CB, another way of modulating CB activity would 
be to directly target its effector, the SNS. The SNS may also represent a putative target to treat 
metabolic diseases related with IR, particularly if modulated regionally in classical insulin-target 
tissues like the skeletal muscle. This pinpoint modulation may be achieved through the use on 
Bioelectronic Medicines, electronic devices connected to individual peripheral nerve fibres, 
aiming to correct pathological electrical patterns and restore health (Famm et al., 2013). This 
new area of therapeutics is emerging right now, with the promise and ambitious goal of 
modulating specific peripheral nerves. Due to the important role the CBs seem to play in both 
the metabolic and hemodynamic control, they represent a natural candidate for Bioelectronic 
Medicines to be tested in a not so distant future.  
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6 Conclusion  
The prevalence of metabolic disorders such as IR and obesity has increased dramatically 
and, despite the efforts that have been made in order to change bad dietary habits and 
sedentary lifestyles, the number of people with T2DM continues to increase. Thus, it is urgent 
to study the pathophysiological mechanisms underlying these and identify strategies for 
prevention and treatment that can help stop this epidemic. 
This study, demonstrates, for the first time, that the abolishment of CB activity can restore 
insulin sensitivity and normalize weight gain, suggesting that the modulation of CB activity can 
be used therapeutically for the treatment of metabolic disturbances.  
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7 Future work 
Despite the novelty of the results here presented and after one year working on this study, 
there are questions that need to be further explored. Therefore as a future project, we still want 
to explore the mechanisms by which CSN resection avoids obesity, and for that we will answer 
to the following questions:   
1) Do these rats lose weight after being denervated due to an increase in energy 
expenditure?  
2) Do these animals have a decreased nutrient consumption and therefore even under 
hypercaloric diets, they lose weight?  
3) Does CSN resection influence adipocyte differentiation?  
4) Can white adipose tissue being converted in brown adipose tissue?  
 
To answer to these questions, experiments will be performed in Wistar rats. Two animal 
models will be used: a prediabetes model obtained by ingestion of a 45% lipid-rich diet during 
3 weeks and a T2DM model obtained by ingestion of 60% lipid-rich diet and 35% sucrose in 
drinking water during 20 weeks.  
CSN resection will be performed in these animals. Insulin sensitivity and glucose tolerance 
will be evaluated; weight, fasting glycemia and insulinemia will be monitored. Energy 
expenditure will be also monitored by measurement of PCO2 and PO2 by gasimetry and by 
functional magnetic resonance of hypothalamic nuclei. After CB denervation, when insulin 
sensitivity and glucose tolerance were restored animals will be submitted to a terminal protocol 
to collect adipose tissue to perform adipocyte volume histology and to study the expression of 
several molecular mediators of brown adipose tissue like  PGC1a and PRDM16 and 
adipogenesis (like C/EBP, SREBP1c and PPAR. Also, activities of lipoprotein lipase (LPL) and 
hormone-sensitive lipase (HSL) will be assessed as markers for adipose tissue metabolism.  
The clarification of weight loss-associated mechanisms induced by CSN denervation will 
open new doors for intervention for the treatment of one of highest pandemics of this century: 
obesity.  
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